The Q-TWiST analysis supports a positive benefit-risk ratio for the combination of ixabepilone plus cape in patients with advanced/metastatic breast cancer that is refractory to anthracyclines and taxanes versus cape alone, despite the potential for added toxicities with combination therapy.
Neurology, Virology, and Immunology, Bristol-Myers Squibb, Wallingford, Connecticut, USA.
Cancer. 2012 Jan;118(2):461-8
© Galenicom 1999-2013